Results of Operations and Financial Condition. On August 12, 2026, the Company issued a press release announcing its financial condition and results of operations for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Securities E…

The company approved retention bonuses for certain executives to ensure their continued employment.

null — Mr. Green: Mr. Green was terminated not-for-cause and a separation agreement was reached.

The excerpt is incomplete and does not provide sufficient information to determine the nature of the event.

Results of Operations and Financial Condition. On May 13, 2026, the Company issued a press release announcing its financial condition and results of operations for the three months ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Ac…

Other Events On July 5, 2024, Forrest A K Wells, a purported stockholder of ours, filed a putative class action complaint in the United States District Court for the District of Colorado, captioned Wells v. SeaStar Medical Holding Corporation et al, Case No. 1:24-cv-0187 (D. Colorado) (the “Class Action”). The Class Action alleges that we, our Chief Executive Officer and former Chief Financial Officer made or caused to be made material misstatements or omissions regarding our business and ope…

Results of Operations and Financial Condition. On March 25, 2026, SeaStar Medical Holding Corp. (the "Company") issued a press release announcing its financial condition and results of operations for the three and twelve months ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for pu…

Change in Reverse Stock Split Date true 0001831868 0001831868 2025-12-18 2025-12-18 0001831868 icu:CommonStockCustomMember 2025-12-18 2025-12-18 0001831868 icu:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockFor1150PerShareCustomMember 2025-12-18 2025-12-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18…

Material Modification to Rights of Security Holders On December 18, 2025, SeaStar Medical Holding Corporation (“the Company”) held a special meeting of the shareholders (the "Special Meeting") during which the stockholders approved a 1-for-10 reverse stock split of the Company's common stock (the "Reverse Split"). The Board of Directors of the Company previously approved the Reverse Split subject to stockholder approval. The Reverse Split will be effective as of 12:01 AM Eastern Standard Time…

Chief Financial Officer — Michael Messinger: The Company appointed Michael Messinger as the new Chief Financial Officer.

Results of Operations and Financial Condition. On November 13, 2025, the Company issued a press release announcing its financial condition and results of operations for the three and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Secu…

The Board approved an increase in the annual base salaries of certain officers and directors, restoring previous levels.

Chief Financial Officer and Treasurer — David Green: The CFO was terminated without cause, leading to significant financial and operational changes.

Results of Operations and Financial Condition. On August 13, 2025, the Company issued a press release announcing its financial condition and results of operations for the three and six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Securities E…

in the EDGAR submission header. This Amendment is being filed through EDGAR to reference the correct Form 8-K Item Numbers (Items 2.02 and 9.01) in the EDGAR submission header. There are no changes to the Original Filing itself (which referenced the correct Item numbers). Except as summarized above, this Amendment continues to speak as of the date of the Original Filing and does not reflect events occurring after the date of the Original Filing or modify or update the disclosures therein in a…

Results of Operations and Financial Condition. On August 13, 2025, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the three and six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for pu…

Other Events As previously disclosed, on August 20, 2024, SeaStar Medical Holding Corporation, (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as sales agent, pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), from time to time in an at-the-market public offering. On July 10, 2025, the Company determined to suspend sales under t…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 31, 2025, SeaStar Medical Holding Corporation (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the minimum $…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 31, 2025, SeaStar Medical Holding Corporation (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the minimum $…

Unregistered Sales of Equity Securities The disclosure regarding the Common Warrants, Common Warrant Shares, Placement Agent Warrants, and Placement Agent Warrant Shares set forth under

Entry into a Material Definitive Agreement Securities Purchase Agreement Registered Direct Offering and Private Placement Securities Purchase Agreement On July 31, 2025, SeaStar Medical Holdings Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company sold and issued to the Purchasers, (i) in a registered direct offering, 4,960,544 shares of the Company’s common st…

Chairman of the Board and Chair of Nominating and Corporate Governance Committee — Rick J. Barnett: Mr. Barnett resigned for personal reasons.

Entry into a Material Definitive Agreement Securities Purchase Agreement On July 10, 2025, SeaStar Medical Holdings Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company sold and issued to the Purchasers, (i) in a registered direct offering, 4,841,232 shares of the Company’s common stock (the “Shares”), par value $0.0001 per share (“Common Stock”), and pre-funde…

Unregistered Sales of Equity Securities The disclosure regarding the Common Warrants, Common Warrant Shares, Placement Agent Warrants, and Placement Agent Warrant Shares set forth under

Executives agreed to waive their earned bonuses to support the company's efforts to reduce liabilities.